The efficiency of Vpx-mediated SAMHD1 antagonism does not correlate with the potency of viral control in HIV-2-infected individuals

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Yu, Hangxing ^a   Usmani, Shariq M ^a   Borch, Alexandra ^a   Krämer, Julia ^a   Stürzel, Christina M ^a   Khalid, Mohammad ^a   Li, Xuehua ^a   Krnavek, Daniela ^a   van der Ende, Marchina E ^b   Osterhaus, Albert D ^b   Gruters, Rob A ^b   Kirchhoff, Frank ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

AIDS; HIV 2; SAMHD1; Viral immune sensing; Vpx

Indexed keywords

PROTEIN; SAMHD1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; CELLULAR IMMUNITY; CONFOCAL MICROSCOPY; DENDRITIC CELL; DRUG POTENCY; GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE; INNATE IMMUNITY; MACROPHAGE; PROTEIN DEGRADATION; VIRUS REPLICATION; VPX GENE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; CELL LINE; CLUSTER ANALYSIS; DENDRITIC CELLS; HIV INFECTIONS; HIV-2; HOST-PATHOGEN INTERACTIONS; HUMANS; MOLECULAR SEQUENCE DATA; MONOMERIC GTP-BINDING PROTEINS; PHYLOGENY; PROTEOLYSIS; SEQUENCE ANALYSIS, DNA; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 84874501701     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-27     Document Type: Article

References (62)

1. Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, Fuller JC, Jackson RM, Lamb T, Briggs TA, Ali M, Gornall H, Couthard LR, Aeby A, Attard-Montalto SP, Bertini E, Bodemer C, Brockmann K, Brueton LA, Corry PC, Desguerre I, Fazzi E, Cazorla AG, Gener B, Hamel BC, Heiberg A, Hunter M, van der Knaap MS, Kumar R, Lagae L, Landrieu PG, Lourenco CM, Marom D, McDermott MF, van der Merwe W, Orcesi S, Prendiville JS, Rasmussen M, Shalev SA, Soler DM, Shinawi M, Spiegel R, Tan TY, Vanderver A, Wakeling EL, Wassmer E, Whittaker E, Lebon P, Stetson DB, Bonthron DT, Crow YJ. Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 2009, 41:829-832. 10.1038/ng.373, 19525956.
2. Berger A, Sommer AF, Zwarg J, Hamdorf M, Welzel K, Esly N, Panitz S, Reuter A, Ramos I, Jatiani A, Mulder LC, Fernandez-Sesma A, Rutsch F, Simon V, König R, Flory E. SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutières syndrome are highly susceptible to HIV-1 infection. PLoS Pathog 2011, 7:e1002425. 10.1371/journal.ppat.1002425, 3234228, 22174685.
3. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011, 474:658-661. 10.1038/nature10195, 3179858, 21720370.
4. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Ségéral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011, 474:654-657. 10.1038/nature10117, 21613998.
5. Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, Walker PA, Kelly G, Haire LF, Yap MW, de Carvalho LP, Stoye JP, Crow YJ, Taylor IA, Webb M. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 2011, 480:379-382. 10.1038/nature10623, 22056990.
6. Powell RD, Holland PJ, Hollis T, Perrino FW. Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J Biol Chem 2011, 286:43596-43600. 10.1074/jbc.C111.317628, 3243528, 22069334.
7. Malim MH, Emerman M. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 2008, 3:388-398. 10.1016/j.chom.2008.04.008, 18541215.
8. Neil S, Bieniasz P. Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res 2009, 29:569-580. 10.1089/jir.2009.0077, 2956573, 19694548.
9. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 2010, 8:55-67. 10.1016/j.chom.2010.06.004, 20638642.
10. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, Bloch N, Maudet C, Bertrand M, Gramberg T, Pancino G, Priet S, Canard B, Laguette N, Benkirane M, Transy C, Landau NR, Kim B, Margottin-Goguet F. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 2012, 13:223-228.
11. Kim B, Nguyen LA, Daddacha W, Hollenbaugh JA. Tight Interplay among SAMHD1 Protein Level, Cellular dNTP Levels, and HIV-1 Proviral DNA Synthesis Kinetics in Human Primary Monocyte-derived Macrophages. J Biol Chem 2012, 287:21570-21574. 10.1074/jbc.C112.374843, 22589553.
12. Laguette N, Rahm N, Sobhian B, Chable-Bessia C, Münch J, Snoeck J, Sauter D, Switzer WM, Heneine W, Kirchhoff F, Delsuc F, Telenti A, Benkirane M. Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. Cell Host Microbe 2012, 11:205-217. 10.1016/j.chom.2012.01.007, 22305291.
13. Lim ES, Fregoso OI, McCoy CO, Matsen FA, Malik HS, Emerman M. The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. Cell Host Microbe 2012, 16:194-204.
14. Ahn J, Hao C, Yan J, DeLucia M, Mehrens J, Wang C, Gronenborn AM, Skowronski J. HIV/simian immunodeficiency virus (SIV) accessory virulence factor Vpx loads the host cell restriction factor SAMHD1 onto the E3 ubiquitin ligase complex CRL4DCAF1. J Biol Chem 2012, 287:12550-12558. 10.1074/jbc.M112.340711, 3321004, 22362772.
15. Zhang C, de Silva S, Wang JH, Wu L. Co-Evolution of Primate SAMHD1 and Lentivirus Vpx Leads to the Loss of the vpx Gene in HIV-1 Ancestor. PLoS One 2012, 7:e37477. 10.1371/journal.pone.0037477, 3345027, 22574228.
16. Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Littman DR. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 2010, 467:214-217. 10.1038/nature09337, 3051279, 20829794.
17. Lopes AR, Jaye A, Dorrell L, Sabally S, Alabi A, Jones NA, Flower DR, De Groot A, Newton P, Lascar RM, Williams I, Whittle H, Bertoletti A, Borrow P, Maini MK. Greater CD8+ TCR heterogeneity and functional flexibility in HIV-2 compared to HIV-1 infection. J Immunol 2003, 171:307-316.
18. Foxall RB, Cortesão CS, Albuquerque AS, Soares RS, Victorino RM, Sousa AE. Gag-specific CD4+ T-cell frequency is inversely correlated with proviral load and directly correlated with immune activation in infection with human immunodeficiency virus type 2 (HIV-2) but not HIV-1. J Virol 2008, 82:9795-9799. 10.1128/JVI.01217-08, 2546953, 18653457.
19. Kong R, Li H, Bibollet-Ruche F, Decker JM, Zheng NN, Gottlieb GS, Kiviat NB, Sow PS, Georgiev I, Hahn BH, Kwong PD, Robinson JE, Shaw GM. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J Virol 2012, 86:947-960. 10.1128/JVI.06155-11, 3255805, 22031948.
20. Zheng NN, Kiviat NB, Sow PS, Hawes SE, Wilson A, Diallo-Agne H, Critchlow CW, Gottlieb GS, Musey L, McElrath MJ. Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal. J Virol 2004, 78:13934-13942. 10.1128/JVI.78.24.13934-13942.2004, 533895, 15564501.
21. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia MC, Gueye EH. Reduced rate of disease development after HIV-2 infection compared to HIV-1. Science 1994, 265:1587-1590. 10.1126/science.7915856, 7915856.
22. Shanmugam V, Switzer WM, Nkengasong JN, García-Lerma G, Green TA, Ekpini E, Sassan-Morokro M, Antunes F, Manshino K, Soriano V, Wiktor SZ, Heneine W. Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections. J Acquir Immune Defic Syndr 2000, 24:257-263.
23. Berry N, Ariyoshi K, Jaffar S, Sabally S, Corrah T, Tedder R, Whittle H. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol 1998, 1:457-468.
24. Simon F, Matheron S, Tamalet C, Loussert-Ajaka I, Bartczak S, Pépin JM, Dhiver C, Gamba E, Elbim C, Gastaut JA. Cellular and plasma virus load in patients infected with HIV-2. AIDS 1993, 7:1411-1417. 10.1097/00002030-199311000-00002, 7904166.
25. da Silva ZJ, Oliveira I, Andersen A, Dias F, Rodrigues A, Holmgren B, Andersson S, Aaby P. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing?. AIDS 2008, 22:1195-1202. 10.1097/QAD.0b013e328300a33d, 18525265.
26. van der Ende ME, Schutten M, Ly TD, Gruters RA, Osterhaus AD. HIV-2 infection in 12 European residents: virus characteristics and disease progression. AIDS 1996, 10:1649-1655. 10.1097/00002030-199612000-00009, 8970685.
27. Blaak H, Boers PH, Gruters RA, Schuitemaker H, van der Ende ME, Osterhaus AD. CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia. J Virol 2005, 79:1686-1700. 10.1128/JVI.79.3.1686-1700.2005, 544080, 15650194.
28. Blaak H, Boers PH, Schutten M, van der Endeñ ME, Osterhaus AD. HIV-2-infected individuals with undetectable plasma viremia carry replication-competent virus in peripheral blood lymphocytes. J Acquir Immune Defic Syndr 2004, 36:777-782. 10.1097/00126334-200407010-00003, 15213560.
29. Blaak H, van der Ende ME, Boers PH, Schuitemaker H, Osterhaus AD. In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology 2006, 353:144-154. 10.1016/j.virol.2006.05.029, 16814357.
30. van der Ende ME, Guillon C, Boers PH, Ly TD, Gruters RA, Osterhaus AD, Schutten M. Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2000, 25:11-18. 10.1097/00126334-200009010-00002, 11064499.
31. Guillon C, van der Ende ME, Boers PH, Gruters RA, Schutten M, Osterhaus AD. Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities. J Virol 1998, 72:6260-6263. 110457, 9621102.
32. Greenberg ME, Iafrate AJ, Skowronski J. The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes. EMBO J 1998, 17:2777-2789. 10.1093/emboj/17.10.2777, 1170618, 9582271.
33. Pancio HA, Vander Heyden N, Ratner L. The C-terminal proline-rich tail of human immunodeficiency virus type 2 Vpx is necessary for nuclear localization of the viral preintegration complex in nondividing cells. J Virol 2000, 74:6162-6167. 10.1128/JVI.74.13.6162-6167.2000, 112115, 10846100.
34. Fujita M, Otsuka M, Nomaguchi M, Adachi A. Functional region mapping of HIV-2 Vpx protein. Microbes Infect 2008, 10:1387-1392. 10.1016/j.micinf.2008.08.005, 18771746.
35. Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, Collin G, Descamps D, Damond F, Brun-Vezinet F, Nisole S, Margottin-Goguet F, Pancino G, Transy C. The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection. J Virol 2009, 83:4854-4860. 10.1128/JVI.00187-09, 2682070, 19264781.
36. Srivastava S, Swanson SK, Manel N, Florens L, Washburn MP, Skowronski J. Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection. PLoS Pathog 2008, 4(5):e1000059. 10.1371/journal.ppat.1000059, 2330158, 18464893.
37. Wei W, Guo H, Han X, Liu X, Zhou X, Zhang W, Yu XF. A novel DCAF1-binding motif required for Vpx-mediated degradation of nuclear SAMHD1 and Vpr-induced G2 arrest. Cell Microbiol 2012, 14:1745-1756. 10.1111/j.1462-5822.2012.01835.x, 22776683.
38. Mahalingam S, Van Tine B, Santiago ML, Gao F, Shaw GM, Hahn BH. Functional analysis of the simian immunodeficiency virus Vpx protein: identification of packaging determinants and a novel nuclear targeting domain. J Virol 2001, 75:362-374. 10.1128/JVI.75.1.362-374.2001, 113929, 11119605.
39. Belshan M, Ratner L. Identification of the nuclear localization signal of human immunodeficiency virus type 2 Vpx. Virology 2003, 311:7-15. 10.1016/S0042-6822(03)00093-X, 12832198.
40. Belshan M, Mahnke LA, Ratner L. Conserved amino acids of the human immunodeficiency virus type 2 Vpx nuclear localization signal are critical for nuclear targeting of the viral preintegration complex in non-dividing cells. Virology 2006, 346:118-126. 10.1016/j.virol.2005.10.036, 16325220.
41. Mahnke LA, Belshan M, Ratner L. Analysis of HIV-2 Vpx by modeling and insertional mutagenesis. Virology 2006, 348:165-174. 10.1016/j.virol.2005.12.023, 16457868.
42. Rajendra Kumar P, Singhal PK, Vinod SS, Mahalingam S. A non-canonical transferable signal mediates nuclear import of simian immunodeficiency virus Vpx protein. J Mol Biol 2003, 331:1141-1156. 10.1016/S0022-2836(03)00853-2, 12927548.
43. Schindler M, Würfl S, Benaroch P, Greenough TC, Daniels R, Easterbrook P, Brenner M, Münch J, Kirchhoff F. Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles. J Virol 2003, 77:10548-10556. 10.1128/JVI.77.19.10548-10556.2003, 228419, 12970439.
44. Schindler M, Münch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, Müller-Trutwin MC, Novembre FJ, Peeters M, Courgnaud V, Bailes E, Roques P, Sodora DL, Silvestri G, Sharp PM, Hahn BH, Kirchhoff F. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006, 125:1055-1067. 10.1016/j.cell.2006.04.033, 16777597.
45. Gao F, Yue L, White AT, Pappas PG, Barchue J, Hanson AP, Greene BM, Sharp PM, Shaw GM, Hahn BH. Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature 1992, 358:495-499. 10.1038/358495a0, 1641038.
46. Gao F, Yue L, Robertson DL, Hill SC, Hui H, Biggar RJ, Neequaye AE, Whelan TM, Ho DD, Shaw GM. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol 1994, 68:7433-7447. 237186, 7933127.
47. Brandariz-Nuñez A, Valle-Casuso JC, White TE, Laguette N, Benkirane M, Brojatsch J, Diaz-Griffero F. Role of SAMHD1 nuclear localization in restriction of HIV-1 and SIVmac. Retrovirology 2012, 9:49. 10.1186/1742-4690-9-49, 3410799, 22691373.
48. Coon S, Wang D, Wu L. Polymorphisms of the SAMHD1 gene are not associated with the infection and natural control of HIV type 1 in Europeans and African-Americans. AIDS Res Hum Retroviruses 2012, 28:1565-1773. 10.1089/aid.2012.0039, 22530776.
49. Price AJ, Marzetta F, Lammers M, Ylinen LM, Schaller T, Wilson SJ, Towers GJ, James LC. Active site remodeling switches HIV specificity of antiretroviral TRIMCyp. Nat Struct Mol Biol 2009, 16:1036-1042. 10.1038/nsmb.1667, 3556581, 19767750.
50. Braaten D, Franke EK, Luban J. Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. J Virol 1996, 70:4220-4227. 190352, 8676442.
51. Sharp PM, Hahn BH. Origins of HIV and the AIDS Pandemic. Cold Spring Harb Perspect Med 2011, 1:a006841. 3234451, 22229120.
52. Duvall MG, Loré K, Blaak H, Ambrozak DA, Adams WC, Santos K, Geldmacher C, Mascola JR, McMichael AJ, Jaye A, Whittle HC, Rowland-Jones SL, Koup RA. Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection. J Virol 2007, 81:13486-13498. 10.1128/JVI.00976-07, 2168847, 17913821.
53. Günthard HF, Huber M, Kuster H, Shah C, Schüpbach J, Trkola A, Böni J. HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia. Clin Infect Dis 2009, 48:e117-e120. 10.1086/598987, 19382874.
54. Greenberg AE. Possible protective effect of HIV-2 against incident HIV-1 infection: review of available epidemiological and in vitro data. AIDS 2001, 15:2319-2321. 10.1097/00002030-200111230-00015, 11698707.
55. Nkengasong JN, Kestens L, Ghys PD, Koblavi-Dème S, Otten RA, Bilé C, Maurice C, Kalou M, Laga M, Wiktor SZ, Greenberg AE. Dual infection with human immunodeficiency virus type 1 and type 2: impact on HIV type 1 viral load and immune activation markers in HIV-seropositive female sex workers in Abidjan, Ivory Coast. AIDS Res Hum Retroviruses 2000, 16:1371-1378. 10.1089/08892220050140919, 11018856.
56. Laguette N, Benkirane M. How SAMHD1 changes our view of viral restriction. Trends Immunol 2012, 33:26-33. 10.1016/j.it.2011.11.002, 22177690.
57. Lim ES, Emerman M. HIV: Going for the watchman. Nature 2011, 474:587-588. 10.1038/474587a, 21720361.
58. St Gelais C, Wu L. SAMHD1: a new insight into HIV-1 restriction in myeloid cells. Retrovirology 2011, 8:55. 10.1186/1742-4690-8-55, 3142215, 21740548.
59. Schaller T, Goujon C, Malim MH. AIDS/HIV. HIV interplay with SAMHD1. Science 2012, 335:1313-1314. 10.1126/science.1221057, 22422971.
60. Accola MA, Bukovsky AA, Jones MS, Göttlinger HG. A conserved dileucine-containing motif in p6(gag) governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm). J Virol 1999, 73:9992-9999. 113050, 10559313.
61. Porcheray F, Viaud S, Rimaniol AC, Léone C, Samah B, Dereuddre-Bosquet N, Dormont D, Gras G. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 2005, 142:481-489. 1809537, 16297160.
62. Khalid M, Yu H, Sauter D, Usmani SM, Schmokel J, Feldman J, Gruters RA, van der Ende ME, Geyer M, Rowland-Jones S, Osterhaus AD, Kirchhoff F. Efficient Nef-mediated downmodulation of TCR-CD3 and CD28 is associated with high CD4+ T cell counts in viremic HIV-2 infection. J Virol 2012, 86:4906-4920. 10.1128/JVI.06856-11, 3347365, 22345473.